IQVIA™ Real-World Insights Bibliography

WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE.
Author(s): Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles
Affiliations(s): RWI IQVIA France
Publication(s):  ISPOR 2018
Document Type(s): Poster,
Countries: France,
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases,
2018
  L:
A:
English
Cost effectiveness, Pricing & Reimbursement, Willingness to pay,
  Add to report
 
 
Overview of German AMNOG Dossiers with Price Analysis Before and After Early Benefit Assessment
Author(s): Tremmel M, Batscheider A, Bocuk D, Roxlau T, Antoni B, Elena Mihaylova, Bonduelle D
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany IQVIA RDS Bulgaria EOOD, Sofia, Bulgaria
Publication(s): 
Document Type(s): Abstract,
Countries: 
C:
Y:
Health economics, Health policy, Pricing and reimbursement,
2018
  L:
A:
English
Pricing & Reimbursement, Review,
  Add to report
 
 
The Impact of Label Extensions on the Reimbursed Price of Pharmaceutical Products Assessed According to §35A SGB V in Germany Oncological and Metabolic Diseases
Author(s): Schmalhofer C, Eheberg D, Tremmel M, Bocuk D, Roxlau T, Antoni B, Bonduelle D
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany
Publication(s): 
Document Type(s): Abstract,
Countries: Germany,
C:
Y:
Health economics, Health policy, Metabolic Disorders , Oncology, Pricing and reimbursement,
2018
  L:
A:
English
Cost analysis, Pricing & Reimbursement,
  Add to report
 
 
Healthcare Resource Utilization and Costs among Psoriasis Patients Treated with Biologics, Overall and by Disease Severity
Author(s): Murage MJ, Anderson A, Oliveria SA, Casso D, Ojeh CK, Muram TM, Merola JF, Araujo AB
Affiliations(s): Murage MJ: Eli Lilly and Company; Anderson A: IQVIA; Oliveria SA: IQVIA; Casso D: IQVIA; Ojeh CK: Eli Lilly and Company; Muram TM: Eli Lilly and Company; Merola JF: Harvard Medical School; Araujo AB: Eli Lilly and Company
Publication(s):  Journal of Medical Economics
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Dermatology, Patient Registries & Real-World Study Methods, Pricing and reimbursement,
2018
  L:
A:
English
Cost analysis, Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis,
  Add to report
 
 
Valoración de la innovación, ¿es “el innovómetro” una herramienta útil y su clasificación reproducible?
Author(s): Otermin A, Callejo D, Gasche D, Viayna E, Rubio M, Sumalla M, Solozabal M.
Affiliations(s): HEOR-RWI, IQVIA
Publication(s):  XXXVIII Jornadas de Economía de la Salud, Gran Canaria 2018
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C:
Y:
Health policy, Pricing and reimbursement,
2018
  L:
A:
Spanish
Pricing & Reimbursement,
  Add to report
 
 
How a new innovation assessment tool relates to recent drug launches for Spanish National acess
Author(s): Míriam Solozabal, Elisabet Viayna, Marta Rubio, Mireia Sumalla, Ane Otermin, David Gasche, Laura Planellas, Daniel Callejo
Affiliations(s): HEOR-RWI, IQVIA Spain
Publication(s):  ISPOR Europe 2018. 10-14 November 2018 | Barcelona, Spain
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C:
Y:
Pricing and reimbursement,
2018
  L:
A:
English
Clinical setting: hospital, Pricing & Reimbursement,
  Add to report
 
 
The impact of biosimilar launch on molecule price and pharmaceutical expense: the case of the insulin glargine in Italy
Author(s): Tucci C1, Cioni L1, Mantuano M1, Tettamanti A1
Affiliations(s): 1 QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Diabetes, Health policy, Pricing and reimbursement, Regulatory,
2017
  L:
A:
English
Literature Review, Pricing & Reimbursement, Public Health,
  Add to report
 
 
Drug commercialization before the pricing and reimbursement in Italy: the non negotiated C Class (C-nn)
Author(s): Mantuano M1, Cioni L1
Affiliations(s): 1 QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Health policy, Pricing and reimbursement, Regulatory,
2017
  L:
A:
English
Literature Review, Pricing & Reimbursement, Public Health,
  Add to report
 
 
Análisis de coste-efectividad de empagliflozina en pacientes con diabetes mellitus tipo 2 y enfermedad cardiovascular establecida en España [Analysis of cost-effectiveness of empagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease established in Spain].
Author(s): Barrull C1, Massafrets M2, Planellas L1, Perulero N1
Affiliations(s): 1 RWI, QuintilesIMS, Barcelona 2 Market Access Department, Boehringer Ingelheim, Barcelona
Publication(s):  XXXVII Jornadas de Economía de la Salud2017, 6 - 8 de septiembre, Barcelona, España
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C:
Y:
Cardiovascular disease, Diabetes, Health economics, Pricing and reimbursement,
2017
  L:
A:
Spanish
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Cost effectiveness, Cost utility, Literature Review, Patient questionnaire, Randomised controlled trial,
  Add to report
 
 
Regional market access pathways for diagnostics in Italy.
Author(s): Mantuano M1, Dionisi M2, Paolini D2, Gancitano G2, Urbinati D1
Affiliations(s): 1 IMS Health, Milan, Italy 2 Roche Diagnostics, Italy.
Publication(s):  ISPOR 19th Annual European Congress, 2016, 29 October-2 November, Vienna, Austria.
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Health policy, Pricing and reimbursement, Regulatory,
2016
  L:
A:
English
Review,
  Add to report
 
 
 1 of 6 Next Page Last Page